TriMas Corporation 2020 Q1 Form 10-Q Summary
Business Context and Reporting Period
TriMas designs and manufactures engineered products serving consumer products, aerospace and defense, and industrial markets through its Packaging, Aerospace, and Specialty Products segments. This unaudited filing covers the three months ended March 31, 2020, compared primarily with the three months ended March 31, 2019.
Lamons was sold in December 2019 for approximately $135 million and is presented as discontinued operations. In February 2020, TriMas acquired RSA Engineered Products for approximately $84.3 million, and its machined components operations were moved from Specialty Products to Aerospace.
Key Financial Metrics
| Metric | Q1 2020 | Q1 2019 | Change |
|---|---|---|---|
| Net sales | $182.8 million | $173.4 million | Up 5.4% |
| Gross profit | $46.4 million | $46.8 million | Down 0.9% |
| Gross margin | 25.4% | 27.0% | Down 160 bps |
| Operating profit | $19.8 million | $19.8 million | Approximately flat |
| Operating margin | 10.8% | 11.4% | Down 60 bps |
| Income from continuing operations | $13.1 million | $14.6 million | Down 9.8% |
| Net income | $13.1 million | $19.1 million | Down 31.3% |
| Diluted EPS | $0.30 | $0.42 | Down $0.12 |
| Operating cash flow | $3.4 million | $15.1 million | Down $11.7 million |
Net income declined primarily because the effective tax rate increased to 18.9% from 7.9%; the prior-year period benefited from discrete tax items and included $4.5 million of income from discontinued operations.
At March 31, 2020, cash and cash equivalents were $206.1 million, total assets were $1.32 billion, and shareholders’ equity was $675.5 million. Total debt consisted of $300.0 million of 4.875% senior notes due 2025 and $150.0 million drawn under the revolving credit facility. Gross debt was approximately $450.0 million, or approximately $243.9 million net of cash based on principal amounts.
Operating cash flow was reduced by a $10.6 million increase in receivables and a $14.8 million decrease in accounts payable and accrued liabilities. Investing cash outflows included $84.3 million for the RSA acquisition and $3.9 million of capital expenditures. Financing activities provided $116.6 million, principally from net revolving-credit borrowings, partially offset by $31.6 million of share repurchases.
Material Changes Versus the Prior Comparable Period
- Packaging sales increased 12.6% to $100.1 million, including approximately $7.5 million from Taplast. Operating profit increased to $18.3 million, but margin declined to 18.3% from 19.9% because of mix and COVID-19-related production inefficiencies.
- Aerospace sales increased 7.3% to $48.9 million, including approximately $3.0 million from RSA. Operating profit declined to $5.1 million from $5.8 million due to RSA purchase-accounting charges, higher selling expenses, unfavorable mix, and production inefficiencies.
- Specialty Products sales declined 13.2% to $33.8 million. Lower construction, HVAC, and upstream oil and gas demand reduced operating profit to $3.4 million from $4.7 million.
- Acquisitions contributed approximately $10.5 million of first-quarter sales, while organic sales excluding currency effects declined approximately $0.1 million. Foreign exchange reduced reported sales by approximately $1.0 million.
- Corporate expenses decreased to $7.0 million from $8.4 million, primarily due to lower professional fees and favorable resolution of a legacy matter. Non-cash stock compensation increased to $1.9 million from $1.3 million.
- TriMas repurchased 1.25 million shares for approximately $31.6 million before temporarily suspending the repurchase program in March to preserve liquidity.
Guidance, Outlook, Risks, and Unusual Items
TriMas withdrew its full-year 2020 guidance because the duration and severity of COVID-19 impacts could not be predicted. Management expected significantly greater pressure in the second quarter and beyond, particularly in Aerospace and Specialty Products, while anticipating continued demand for Packaging products used in hygiene, cleaning, and related applications.
Most manufacturing sites remained open as essential operations, but certain facilities experienced temporary shutdowns, absenteeism, social-distancing inefficiencies, and supply-chain disruption. Management was evaluating cost reductions, realignment actions, capacity changes, and manufacturing-footprint adjustments.
- Potential future charges include restructuring and realignment costs, customer-credit losses, excess inventory, idle equipment, and goodwill or intangible-asset impairment, particularly in Aerospace. The filing does not provide a clear estimate of these potential charges.
- TriMas had $131.2 million of revolver availability after outstanding letters of credit at March 31, 2020. Management stated that liquidity and covenant headroom were sufficient for foreseeable obligations.
- Actual covenant ratios were 2.19x total net leverage versus a 4.00x limit, 0.31x senior secured net leverage versus a 3.50x limit, and 13.63x interest coverage versus a 3.00x minimum. The company was in compliance.
- Asbestos litigation involved 348 pending cases and 4,719 claims. Management did not believe the matters would materially affect financial position, results, or cash flows, but acknowledged potential for additional claims and costs.
- On April 17, 2020, after quarter-end, TriMas paid approximately $11.4 million to acquire the Rapak bag-in-box product lines and related assets, which generated approximately $30 million of 2019 sales.
Important Facts for Investors to Verify
- COVID-19’s effect on second-quarter and full-year sales, margins, production capacity, and customer demand.
- Whether Aerospace and Specialty Products weakness leads to restructuring, inventory, credit, or impairment charges.
- Post-RSA integration, expected synergies, purchase-accounting effects, and the impact of the Rapak acquisition.
- Operating cash-flow conversion and working-capital trends, particularly receivables and supplier payments.
- Revolver utilization, interest-rate exposure, covenant headroom, and refinancing requirements for the 2025 senior notes.
- The future of the suspended share-repurchase program and its effect on liquidity.
- Developments in asbestos claims, insurance coverage, and related defense and settlement costs.